Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both

Journal of the American College of Cardiology

Volumn 51, Issue 19, 2008, Pages 1865-1871

  Prisant, L Michael ^a   Thomas, Kevin L ^b   Lewis, Eldrin F ^c   Huang, Zhen ^b   Francis, Gary S ^d   Weaver, W Douglas ^e   Pfeffer, Marc A ^c   McMurray, John J V ^f   Califf, Robert M ^b   Velazquez, Eric J ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^f WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CAPTOPRIL PLUS VALSARTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERTENSIVE FACTOR; INSULIN; NITRATE; NITRIC ACID DERIVATIVE; POTASSIUM SPARING DIURETIC AGENT; VALSARTAN; VASODILATOR AGENT;

ACUTE HEART INFARCTION; ADULT; AFRICAN AMERICAN; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; COUGHING; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EUROPEAN AMERICAN; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HOSPITAL READMISSION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; PARAMETER; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT DISEASE; REVASCULARIZATION; SINGLE BLIND PROCEDURE; STROKE; TASTE DISORDER; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT;

AFRICAN AMERICANS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CAPTOPRIL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SYSTOLE; TETRAZOLES; UNITED STATES; VALINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 42949091928     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.12.050     Document Type: Article

References (38)

1. Gheorghiade M., and Bonow R.O. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 97 (1998) 282-289
2. Cooper R., Cutler J., Desvigne-Nickens P., et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 102 (2000) 3137-3147
3. Yancy C.W. Heart failure in African Americans: pathophysiology and treatment. J Card Fail 9 (2003) S210-S215
4. Dries D.J., Yancy C.W., Strong M.A., and Drazner M.H. Racial response to angiotensin-converting enzyme therapy in systolic heart failure. Congest Heart Fail 10 (2004) 30-33
5. Dries D.L., Exner D.V., Gersh B.J., et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 340 (1999) 609-616
6. Pfeffer M.A., Braunwald E., Moye L.A., et al., The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327 (1992) 669-677
7. Ambrosioni E., Borghi C., and Magnani B. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 332 (1995) 80-85
8. Køber L., Torp-Pedersen C., Carlsen J.E., et al., Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333 (1995) 1670-1676
9. Swedberg K., Held P., Kjekshus J., Rasmussen K., Rydén L., and Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327 (1992) 678-684
10. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 (1993) 821-828
11. Dickstein K., and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 (2002) 752-760
12. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
13. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
14. Carson P., Ziesche S., Johnson G., Cohn J.N., and Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 5 (1999) 178-187
15. Pfeffer M.A., McMurray J., Leizorovicz A., et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 140 (2000) 727-750
16. Peterson E.D., Shaw L.K., DeLong E.R., et al. Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter?. N Engl J Med 336 (1997) 480-486
17. Conigliaro J., Whittle J., Good C.B., et al. Understanding racial variation in the use of coronary revascularization procedures: the role of clinical factors. Arch Intern Med 160 (2000) 1329-1335
18. Schulman K.A., Berlin J.A., Harless W., et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med 340 (1999) 618-626
19. Chen J., Rathore S.S., Radford M.J., Wang Y., and Krumholz H.M. Racial differences in the use of cardiac catheterization after acute myocardial infarction. N Engl J Med 344 (2001) 1443-1449
20. Agodoa L.Y., Appel L., Bakris G.L., et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285 (2001) 2719-2728
21. Wright Jr. J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288 (2002) 2421-2431
22. Julius S., Alderman M.H., Beevers G., et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol 43 (2004) 1047-1055
23. Exner D.V., Dries D.L., Domanski M.J., and Cohn J.N. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 344 (2001) 1351-1357
24. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343 (1994) 1115-1122
25. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 345 (1995) 686-687
26. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345 (1995) 669-685
27. Moye L.A., Pfeffer M.A., Braunwald E., and SAVE Investigators. Rationale, design and baseline characteristics of the survival and ventricular enlargement trial. Am J Cardiol 68 (1991) 70D-79D
28. Moye L.A., Pfeffer M.A., Wun C.C., et al. Uniformity of captopril benefit in the SAVE study: subgroup analysis. Survival and Ventricular Enlargement Study. Eur Heart J 15 (1994) 2-8
29. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in black patients with heart failure. N Engl J Med 351 (2004) 2049-2057
30. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344 (2001) 1659-1667
31. Garg R., Yusuf S., and Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273 (1995) 1450-1456
32. Yancy C.W., Benjamin E.J., Fabunmi R.P., and Bonow R.O. Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: executive summary. Circulation 111 (2005) 1339-1349
33. Neaton J.D., Grimm Jr. R.H., Prineas R.J., et al., Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study. Final results. JAMA 270 (1993) 713-724
34. Prisant L.M., and Mensah G.A. Use of beta-adrenergic receptor blockers in black patients. J Clin Pharmacol 36 (1996) 867-873
35. Saunders E., Weir M.R., Kong B.W., et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive black patients. Arch Intern Med 150 (1990) 1707-1713
36. Mokwe E., Ohmit S.E., Nasser S.A., et al. Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation trial. Hypertension 43 (2004) 1202-1207
37. Weir M.R., Gray J.M., Paster R., Saunders E., and The Trandolapril Multicenter Study Group. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. Hypertension 26 (1995) 124-130
38. Prisant L.M. Angioneurotic edema. J Clin Hypertens 3 (2001) 262-263